Rani Therapeutics Holdings, Inc.
RANI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001856725
In the last 90 days, Rani Therapeutics Holdings, Inc. insiders filed 2 open-market purchases and 2 sales; 68 institutions reported holding it in 13F filings for Q2 2026, worth $34.7M in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $50.0K in total
- 2
- Insider sellsLast 90 days, $11.6K in total
- 2
- 13F holdersQ2 2026, −5 vs. previous quarter
- 68
- 13F valueReported value at the end of Q2 2026
- $34.7M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding RANI, Q2 2026
No superinvestor reported holding RANI at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Rani Therapeutics Holdings, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 23, 2026 (view filing)4:10 PM ET | Jul 21 | 2 days | Imran Mir ADirector, 10% Owner | PPurchaseClass A Common Stock | +36.0K | $0.69 | +$24.8K | +1.7%2.12M after | |
| Jul 21, 2026 (view filing)7:24 PM ET | Mar 27 | 116 daysLate | Javadi AlirezaChief Technical Officer | SSaleClass A Common Stock | −386 | $0.78 | −$301.08 | −3.8%9.69K after | |
| Jul 21, 2026 (view filing)6:29 PM ET | Jul 17 | 4 days | Imran TalatChief Executive Officer | PPurchaseClass A Common Stock | +35.0K | $0.7198 | +$25.2K | +8.1%469.7K after | |
| Jul 21, 2026 (view filing)6:25 PM ET | Dec 27, 2024 | 571 daysLate | Imran TalatChief Executive Officer | SSaleClass A Common Stock | −8.01K | $1.41 | −$11.3K | −1.6%486.7K after | |
| Oct 27, 2025 (view filing) | Oct 23 | 4 days | Imran Mir ADirector, 10% Owner | PPurchaseClass A Common Stock | +2.08M | $0.61 | +$1.27M | New position2.08M after | |
| Oct 27, 2025 (view filing) | Oct 23 | 4 days | Imran Mir ADirector, 10% Owner | PPurchaseClass A Common Stock | +2.08M | $0.00 | $0 | –2.08M after | Derivative |
| Oct 22, 2025 (view filing) | Oct 20-21 | 2 days | South Cone Investments Limited Partnership10% Owner | SSaleClass A Common Stock | −5.92M | $2.65 | −$15.7M | −71.3%2.38M after | 2 lots |
| Dec 16, 2024 (view filing) | Dec 13 | 3 days | McKinley KateChief Business Officer | PPurchaseClass A Common Stock | +18.0K | $1.67 | +$30.0K | New position18.0K after | |
| Dec 10, 2024 (view filing) | Dec 9 | 1 day | Imran TalatChief Executive Officer | PPurchaseClass A Common Stock | +10.3K | $1.94 | +$20.0K | +2.1%494.8K after | |
| Oct 17, 2024 (view filing)4:30 PM ET | Oct 15 | 2 days | South Lake One LLC and 1 other10% Owner | SSaleClass A Common Stock | −3.83M | $2.65 | −$10.1M | −31.6%8.30M after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Rani Therapeutics Holdings, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Samsara BioCapital, LLC | 10,369,159 | $7.88M | 0.65% | +1,869,159+22.0% | Added |
| Ra Capital Management, L.P. | 8,500,000 | $6.46M | 0.06% | 00.0% | Unchanged |
| AWM Investment Company, Inc. | 7,500,000 | $5.70M | 0.49% | +1,000,000+15.4% | Added |
| Vanguard Capital Management LLC | 4,562,985 | $3.47M | 0.00% | −59,582−1.3% | Reduced |
| Longaeva Partners L.P. | 2,329,459 | $1.77M | 0.05% | 00.0% | Unchanged |
| Polar Asset Management Partners Inc. | 2,318,542 | $1.76M | 0.03% | +2,318,542 | New |
| Siren, L.L.C. | 2,000,000 | $1.52M | 0.03% | 00.0% | Unchanged |
| Heights Capital Management, Inc | 934,580 | $710.7K | 0.16% | +934,580 | New |
| Geode Capital Management, LLC | 890,618 | $677.6K | 0.00% | −12,680−1.4% | Reduced |
| Citadel Advisors LLC | 641,995 | $488.2K | 0.00% | +641,995 | New |